# Guava Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guava-technologies

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.guavatechnologies.com
- Total disclosed funding: $27M
- Latest round: Series D (Dec 18, 2003)
- Investors on record: 9

## About

Guava Technologies is a biotechnology company that develops innovative solutions for cell analysis, providing advanced technologies that enhance research capabilities in various scientific fields.Guava Technologies specializes in cell analysis solutions with a focus on advanced flow cytometry systems. The company is based in Hayward, US. In 2009, Guava Technologies raised USD 4.5 mn in VC funding from Hercules Technology Growth Capital, which represents the total amount raised by the company. There are no known subsidiaries or parent companies, nor pivots in business strategy since its founding.Guava Technologies offers innovative cell analysis solutions through its advanced full spectrum flow cytometry systems. Key products include the Cytek Aurora™ and Cytek Northern Lights™, enabling researchers to perform multiplexed experiments with up to 40 colors simultaneously. Their products cater to diverse scientific fields such as immuno-oncology and drug discovery, serving a global clientele including academic institutions and pharmaceutical companies across North America, Europe, and Asia.Guava Technologies generates revenue through direct sales of its flow cytometry systems and associated reagents, focusing on B2B transactions with research institutions. Their product offerings include consumables and hardware, with flagship products like the Cytek Aurora™ driving sales. The company collaborates with software partners to enhance data analysis capabilities, ensuring integration with customer workflows.In March 2009, Guava Technologies raised USD 4.5 mn in VC funding, which will be directed towards developing new products and enhancing their market presence. The company plans to expand into new geographic regions and enhance its product line, although specific markets and release dates have not been disclosed.

## Funding rounds

- Series D, Dec 18, 2003, $27M — Abingworth, Integra Ventures, Granite Asia, Skyline Ventures, HLM Venture Partners, Peninsula Ventures, ProQuest Investments, Stanford University, Canadian Medical Discoveries Fund Inc.

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series D
- Integra Ventures (https://capitalatlas.ai/funds/integra-ventures) — Series D
- Granite Asia (https://capitalatlas.ai/funds/granite-asia) — Series D
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series D
- HLM Venture Partners (https://capitalatlas.ai/funds/hlm-venture-partners) — Series D
- Peninsula Ventures (https://capitalatlas.ai/funds/peninsula-ventures) — Series D
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series D
- Stanford University — Series D
- Canadian Medical Discoveries Fund Inc. — Series D